To the best of our knowledge, this study is the first to report that high expression levels of specific FGFRs and FGFs (FGFR1 with FGF2 or FGF9; FGFR2 with FGF2, FGF7, or FGF9; FGFR3 with FGF2) at baseline rapidly promotes tolerance and continuously maintains survival and growth of DTP and resistant cells during treatment with targeted TKIs in various driver oncogene-positive cancer cells, including those with ALK, EGFR, HER2, or BRAF mutations. Here, ERBB2 is linked to cancer.